Skip to main content
Clinical Trials/ITMCTR2000003951
ITMCTR2000003951
Not yet recruiting
Phase 1

Clinical study on precise diagnosis and treatment of refractory gastroesophageal reflux disease by Traditional Chinese medicine based on intestinal microecological macroomics technology

Shanghai Traditional Chinese Medicine Hospital0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Shanghai Traditional Chinese Medicine Hospital
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Shanghai Traditional Chinese Medicine Hospital

Eligibility Criteria

Inclusion Criteria

  • The research content 1
  • 1\.Inclusion criteria for subjects with refractory gastroesophageal reflux disease
  • A. Meet the diagnostic criteria of gastroesophageal reflux disease;
  • B. Eight weeks of standard PPI treatment for failure with gastroesophageal reflux disease prior to this study;
  • C. Between the ages of 18 and 65, regardless of gender;
  • D. The patient is informed and signs the informed consent.
  • 2\.Inclusion criteria for healthy subjects:
  • A. Healthy volunteers who had physical examination in our hospital;
  • B. Between the ages of 18 and 65, regardless of gender;
  • C. The patient is informed and signs the informed consent.

Exclusion Criteria

  • The research content 1
  • A. Patients with one of the following diseases: peptic ulcer, history of gastroesophageal and duodenal surgery, Zo\-AIDS syndrome, primary esophageal motional diseases (such as achalasia of cardia, scleroderma, primary esophageal spasm), malignant lesions of upper digestive tract, coronary heart disease, diabetes, drug esophagitis.
  • B. Pregnant or lactating women,
  • C. Allergic constitution and psychosis.
  • D. The patient was a researcher directly involved in this clinical study.
  • E. Simultaneous use of drugs that may affect the efficacy and safety of drugs.
  • F. It was considered that there were any circumstances unsuitable for inclusion in the study.
  • The research content 2
  • A. Patients with one of the following diseases: peptic ulcer, history of gastroesophageal and duodenal surgery, Zo\-AIDS syndrome, primary esophageal motional diseases (such as achalasia of cardia, scleroderma, primary esophageal spasm), malignant lesions of upper digestive tract, coronary heart disease, diabetes, drug esophagitis.
  • B. Pregnant or lactating women,

Outcomes

Primary Outcomes

Not specified

Similar Trials